Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Clinical trial NCT05037669 · WITHDRAWN
Trial details
- NCT number
- NCT05037669
- Sponsor
- University of Pennsylvania
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2025-01-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.